{"title":"Auger Electron Therapy Enhanced by Heat-Triggered Release of I-125-Labeled DNA-Targeted Compounds within the Tumor Microenvironment","authors":"Masayuki Munekane, Kazuki Matsunaga, Miki Ozaki, Hiroaki Echigo, Kenji Mishiro, Takeshi Fuchigami, Kazuma Ogawa","doi":"10.1021/acs.molpharmaceut.6c00443","DOIUrl":null,"url":null,"abstract":"<p>In Auger electron therapy, the effective delivery of\r\nAuger electron-emitting\r\nradionuclides to the nuclei of cancer cells is essential for achieving\r\nhigh therapeutic efficacy. In this study, we developed a novel strategy\r\nthat combined thermosensitive liposomes (TSLs) encapsulating <sup>125</sup>I-labeled DNA-targeted compounds. This approach enabled\r\nenhanced tumor accumulation via TSL-mediated delivery and efficient\r\nnuclear translocation of radioactivity by releasing an <sup>125</sup>I-labeled doxorubicin derivative ([<sup>125</sup>I]I-DOX) within\r\nthe tumor microenvironment. [<sup>125</sup>I]I-DOX exhibited high\r\ncellular and nuclear uptake, producing potent cytotoxicity through\r\nAuger electrons emitted from <sup>125</sup>I. [<sup>125</sup>I]I-DOX-loaded\r\nTSLs efficiently released [<sup>125</sup>I]I-DOX at 43 °C, enhancing\r\nits cellular uptake by Colon-26 cells. Tumor accumulation of radioactivity\r\nin the heating group was much higher than in the nonheating group,\r\nand the accumulation was maintained for up to 48 h postinjection.\r\nIntravenous injection of [<sup>125</sup>I]I-DOX-loaded TSLs (5.0 MBq)\r\nand localized tumor heating significantly inhibited tumor growth without\r\nbody weight loss. The combination of [<sup>125</sup>I]I-DOX-loaded\r\nTSLs and hyperthermia represents a promising strategy for Auger electron\r\ntherapy targeting the nuclei of cancer cells.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 9","pages":"4681–4689"},"PeriodicalIF":4.9000,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.6c00443","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
In Auger electron therapy, the effective delivery of
Auger electron-emitting
radionuclides to the nuclei of cancer cells is essential for achieving
high therapeutic efficacy. In this study, we developed a novel strategy
that combined thermosensitive liposomes (TSLs) encapsulating 125I-labeled DNA-targeted compounds. This approach enabled
enhanced tumor accumulation via TSL-mediated delivery and efficient
nuclear translocation of radioactivity by releasing an 125I-labeled doxorubicin derivative ([125I]I-DOX) within
the tumor microenvironment. [125I]I-DOX exhibited high
cellular and nuclear uptake, producing potent cytotoxicity through
Auger electrons emitted from 125I. [125I]I-DOX-loaded
TSLs efficiently released [125I]I-DOX at 43 °C, enhancing
its cellular uptake by Colon-26 cells. Tumor accumulation of radioactivity
in the heating group was much higher than in the nonheating group,
and the accumulation was maintained for up to 48 h postinjection.
Intravenous injection of [125I]I-DOX-loaded TSLs (5.0 MBq)
and localized tumor heating significantly inhibited tumor growth without
body weight loss. The combination of [125I]I-DOX-loaded
TSLs and hyperthermia represents a promising strategy for Auger electron
therapy targeting the nuclei of cancer cells.
期刊介绍:
Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development.
Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.